Our research focuses on improving the outcomes of children with cancer

“There are always new doors waiting to be opened.”
Professor Martin Horstmann


“Since the founding of our institute we have made progress in each of our projects. If you consider that 80 percent of all research endeavors lead to dead ends, this is a remarkable success rate. You can call it luck - or more aptly - intelligent formulation of hypotheses during the project launch phase. And yet, in each additional room we enter, we discover new doors waiting to be opened. These doors are our motivation to continue - for the health of children.”
Professor Martin Horstmann, scientific director of the institute

The Institute

Thanks to successful research, great advancements have been in recent decades in the fight against childhood cancer. Today, in many cases the disease can be treated and cured. About 80 percent of all children diagnosed with cancer survive. However, cancer is still the second-leading cause of death in children and adolescents in Germany.

In the Research Institute Children’s Cancer Center Hamburg we are therefore seeking new approaches to diagnosis and treatment. We want to become even more effective in combating cancer, with a faster response and more targeted treatment. Only by understanding how cancer happens on the molecular level can we develop new approaches to treatment.

The Research Institute was opened on October 1, 2006 by the Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V. The innovative endeavor was made possible through the generous support of the private-sector together with the Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany.

At the Research Institute, we are taking specific long-term steps to advance oncological research under an endowed chair for molecular oncology sponsored by the Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V. We work closely in networks with university institutions and actively promote training programs for scientists and physicians.